Clinical reports on cancer

Chronic kidney disease

Male in the 90s
Chief Complaint: Dyspnea
Past Medical History: Peritonitis

Current Medical History:
He was being treated at a nearby hospital for the above diagnosis, but visited a local doctor on April 28, 2016, due to the appearance of fatigue. He was hospitalized with a high potassium level of 7.9. The potassium levels then normalized, but HOT therapy (home oxygen therapy) was started due to worsening COPD symptoms and chronic respiratory failure. He was hospitalized for continuous care due to difficulty in home care.

Treatment Outcomes:
Upon closer examination, he had a thoracoabdominal effusion.
As he had already been on medical treatment, the combination use of CUA fucoidan resulted in a decrease in thoracic ascites and oxygenation. NT-proBNP also decreased.

※Data taken over the period of treatment

《CT images of the chest》
Fucoidan Mix AG intake per day: Approximately 1.0g (August 2016)
Fucoidan Mix AG intake per day: Approximately 0.5g (October 2016)

clinical_index08_02
August 2016
clinical_index08_02
October 2016
clinical_index08_02
January 2017

 

《CT images of the abdomen》
Fucoidan Mix AG intake per day: Approximately 1.0g (August 2016)
Fucoidan Mix AG intake per day: Approximately 0.5g (October 2016)

clinical_index08_02
August 2016
clinical_index08_02
October 2016

 

【Tumor markers】
Fucoidan Mix AG intake per day: Approximately 1.0g (August 2016)
Fucoidan Mix AG intake per day: Approximately 0.5g (Unknown)

June 2016 January 2017
NT-proBNP (＜ 125) 3560 1854 (pg/ml)


Fucoidan Mix AG・・・It is composed of mozuku extracted fucoidan, mekabu extracted fucoidan and agaricus mycelium.

Today, active research is conducted on fucoidan and various bioactive functions of fucoidan, such as “anti-cancer action,” “cholesterol-lowering action,” “blood-pressure lowering action” and “anti-virus action,” have been revealed.

Back to Top